SEOM Clinical guidelines for the treatment of metastatic prostate cancer
Clin. transl. oncol. (Print)
; 16(12): 1060-1066, dic. 2014.
Article
in English
| IBECS
| ID: ibc-129876
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently require (AU)
RESUMEN
No disponible
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Prostatic Neoplasms
/
Androgens
/
Antineoplastic Agents
Type of study:
Practice guideline
Aspects:
Patient-preference
Limits:
Humans
/
Male
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2014
Document type:
Article
Institution/Affiliation country:
Fundación Instituto Valenciano de Oncología/Spain
/
Hospital Clínic de Barcelona/Spain
/
Hospital Universitari Son Espases/Spain
/
Hospital Universitario Virgen Macarena/Spain
/
Hospital Universitario de Guadalajara/Spain